Sava Infond d.o.o. Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Sava Infond d.o.o. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,700 shares of the company’s stock after acquiring an additional 2,200 shares during the quarter. Sava Infond d.o.o.’s holdings in Novo Nordisk A/S were worth $1,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL boosted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the period. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $29,000. Transce3nd LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $39,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $40,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 5.4%

Shares of NYSE:NVO opened at $69.81 on Tuesday. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The firm has a market capitalization of $313.27 billion, a P/E ratio of 20.65, a P/E/G ratio of 1.32 and a beta of 0.66. The stock has a 50 day moving average price of $68.49 and a 200-day moving average price of $77.98. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion during the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NVO. Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. BMO Capital Markets reaffirmed a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Finally, BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an “underperform” rating for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.